Icatibant Ethypharm (Icatibant)

Icatibant is a competitive antagonist of the bradykinin B2 receptor. By binding to this receptor, it blocks the action of bradykinin, a peptide that increases vascular permeability and causes the swelling characteristic of HAE. This blockade limits edema formation during an attack.

The prescribed dose of Icatibant Ethypharm is determined by the treating physician. Typically, a single subcutaneous injection of the 30 mg/1 mL solution is administered at the onset of an HAE attack, with additional doses given only if clinically required.

Safety data for Icatibant in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers will evaluate the individual situation before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Icatibant Ethypharm. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and the necessary import documentation.

The primary alternative to Icatibant is plasma‑derived or recombinant C1‑inhibitor concentrate, which replaces the deficient protein. Icatibant directly blocks bradykinin receptors, offering a rapid, protein‑free option that can be self‑administered subcutaneously, whereas C1‑inhibitor products are administered intravenously and require protein handling.

Icatibant Ethypharm should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product must be transported, maintain the cold chain throughout the journey.

The medication is supplied as a sterile solution for injection. A healthcare professional (or a trained patient) administers a single subcutaneous injection into the abdomen or thigh using the pre‑filled syringe. The injection site should be rotated for subsequent doses if required.

The most serious adverse events include severe allergic reactions such as anaphylaxis, unexpected angioedema unrelated to HAE, and significant hypotension. Patients should be monitored after injection, and any signs of systemic allergic response require immediate medical attention.

Icatibant is contraindicated in individuals with known hypersensitivity to the active ingredient or any excipients in the formulation. Patients with a history of severe allergic reactions to bradykinin B2 antagonists should avoid its use.